Screener
Supernus Pharmaceuticals SUPN Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001356576-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Amortization of intangible assets | 25,644 | 19,786 |
| Contingent consideration loss | 2,391 | 7,660 |
| Total costs and expenses | 216,037 | 160,080 |
| Operating loss | (8,332) | (10,256) |
| Other income (expense) | ||
| Interest and other income, net | 2,382 | 4,425 |
| Total other income (expense), net | 2,382 | 4,425 |
| Loss before income taxes | (5,950) | (5,831) |
Item 1. Unaudited Condensed Consolidated Financial Statements
FAQ
- What is Supernus Pharmaceuticals's operating income?
- Supernus Pharmaceuticals (SUPN) reported operating income of -$8.33M in Q1 2026.
- How has Supernus Pharmaceuticals's operating income changed year-over-year?
- Supernus Pharmaceuticals's operating income increased by 18.8% year-over-year, from -$10.26M to -$8.33M.
- What is the long-term trend for Supernus Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's operating income has grown at a -7.8% compound annual growth rate (CAGR), from $86.03M to -$62.28M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Supernus Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude